FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979874966> ?p ?o ?g. }

• W2979874966 abstract "Abstract Abstract 854 Background: Residual abnormalities of uncertain significance are frequently seen on post-therapy CT scans in patients (pts) with advanced-stage diffuse large B-cell lymphoma (DLBCL) following treatment with R-CHOP. However, the value of consolidative radiation therapy (XRT) to these sites is unknown. FDG-PET scanning may allow for the discriminate use of XRT to eradicate sites of residual disease. Method: Since 2005, pts with advanced-stage DLBCL in British Columbia (BC) have been treated with a systematic policy recommending a post-chemotherapy PET scan for pts with residual abnormalities ≥2cm on CT scan, followed by XRT to PET-positive sites that are amenable to radiation. Pts with a negative PET scan are observed (regardless of initial or residual bulk), while pts with a PET scan that is widely positive and not suitable for XRT are treated at the discretion of individual physicians. All PET scans are performed in a central location using a combined PET/CT scanner; staging PET scans are not routinely performed. Using the databases of the BC Cancer Agency Centre for Lymphoid Cancer and Department of Functional Imaging, we identified all pts with newly diagnosed advanced-stage DLBCL between January 2005 and June 2009 treated with R-CHOP who underwent a post-treatment PET scan based on this management algorithm. This analysis does not include pts with primary progressive disease; pts with a complete remission on post-treatment CT scan; pts who were HIV positive; or those with transformed lymphoma. Results: 196 pts were identified with the following baseline characteristics: median age 64 y (range 18–89 y); 61% male; 62% stage III/IV; 41% PS>1; 21% >1 extranodal site; 57% elevated LDH; 46% bulky site ≥10cm; 56% IPI 0–2, 44% IPI 3–5. All pts received 3-weekly R-CHOP (6-8 cycles) with curative intent. Median follow-up for living pts is 32 mos (range 5–65 mos). 121/196 (62%) had a negative post-therapy PET (PET-Neg), 66/196 (34%) had a positive PET (PET-Pos), and 9 (4%) were indeterminate. Median SUV of PET-Pos scans was 3.4 (range 1.8–25). None of the PET-Neg pts received XRT. 51/66 (77%) of PET-Pos pts received XRT (3000-4000 cGy) to sites of PET positivity (46 single field, 5 multiple fields), with only 7 relapses to date. 15/66 (23%) PET-Pos pts did not receive XRT due to: multiple sites not amenable to XRT 11; physician choice 3; biopsy negative 1. Only 3/9 pts (33%) with an indeterminate PET received XRT. There was no difference in the 3-y PFS (80% v 75%, p=0.41) and 3-y OS (84% v 77%, p=0.10) between the PET-Neg and PET-Pos pts, respectively. The 3-y PFS was similar for PET-Pos pts who received XRT (84%) and PET-Neg pts (80%) and was superior to PET-Pos pts who did not receive XRT (42%). Pts with an indeterminate scan had a favorable outcome with a 3-y PFS of 89%. Conclusion: Pts with advanced-stage DLBCL who have residual abnormalities on CT scan following R-CHOP and receive consolidative radiation to sites of PET positivity have an outcome similar to pts with a negative post-therapy PET. The favorable outcome observed in the PET-positive cohort treated with XRT is higher than expected from historical reports, suggesting a benefit for the rational use of PET-guided XRT following chemotherapy for DLBCL. Pts who have residual abnormalities on CT scan that are PET-negative should be spared indiscriminate exposure to radiation as the majority have been cured with systemic therapy. Disclosures: No relevant conflicts of interest to declare." @default.
• W2979874966 created "2019-10-18" @default.
• W2979874966 creator A5004614891 @default.
• W2979874966 creator A5017873196 @default.
• W2979874966 creator A5021276970 @default.
• W2979874966 creator A5022658681 @default.
• W2979874966 creator A5023202154 @default.
• W2979874966 creator A5026641386 @default.
• W2979874966 creator A5031758990 @default.
• W2979874966 creator A5035971946 @default.
• W2979874966 creator A5037428122 @default.
• W2979874966 creator A5040772609 @default.
• W2979874966 creator A5070464513 @default.
• W2979874966 date "2010-11-19" @default.
• W2979874966 modified "2023-09-29" @default.
• W2979874966 title "FDG-PET Scan Guided Consolidative Radiation Therapy Optimizes Outcome In Patients with Advanced-Stage Diffuse Large B-Cell Lymphoma (DLBCL) with Residual Abnormalities on CT Scan Following R-CHOP" @default.
• W2979874966 doi "https://doi.org/10.1182/blood.v116.21.854.854" @default.
• W2979874966 hasPublicationYear "2010" @default.
• W2979874966 type Work @default.
• W2979874966 sameAs 2979874966 @default.
• W2979874966 citedByCount "6" @default.
• W2979874966 countsByYear W29798749662012 @default.
• W2979874966 countsByYear W29798749662015 @default.
• W2979874966 countsByYear W29798749662016 @default.
• W2979874966 countsByYear W29798749662020 @default.
• W2979874966 crossrefType "journal-article" @default.
• W2979874966 hasAuthorship W2979874966A5004614891 @default.
• W2979874966 hasAuthorship W2979874966A5017873196 @default.
• W2979874966 hasAuthorship W2979874966A5021276970 @default.
• W2979874966 hasAuthorship W2979874966A5022658681 @default.
• W2979874966 hasAuthorship W2979874966A5023202154 @default.
• W2979874966 hasAuthorship W2979874966A5026641386 @default.
• W2979874966 hasAuthorship W2979874966A5031758990 @default.
• W2979874966 hasAuthorship W2979874966A5035971946 @default.
• W2979874966 hasAuthorship W2979874966A5037428122 @default.
• W2979874966 hasAuthorship W2979874966A5040772609 @default.
• W2979874966 hasAuthorship W2979874966A5070464513 @default.
• W2979874966 hasConcept C126322002 @default.
• W2979874966 hasConcept C126838900 @default.
• W2979874966 hasConcept C146357865 @default.
• W2979874966 hasConcept C151730666 @default.
• W2979874966 hasConcept C2778559949 @default.
• W2979874966 hasConcept C2779338263 @default.
• W2979874966 hasConcept C2989005 @default.
• W2979874966 hasConcept C509974204 @default.
• W2979874966 hasConcept C71924100 @default.
• W2979874966 hasConcept C86803240 @default.
• W2979874966 hasConceptScore W2979874966C126322002 @default.
• W2979874966 hasConceptScore W2979874966C126838900 @default.
• W2979874966 hasConceptScore W2979874966C146357865 @default.
• W2979874966 hasConceptScore W2979874966C151730666 @default.
• W2979874966 hasConceptScore W2979874966C2778559949 @default.
• W2979874966 hasConceptScore W2979874966C2779338263 @default.
• W2979874966 hasConceptScore W2979874966C2989005 @default.
• W2979874966 hasConceptScore W2979874966C509974204 @default.
• W2979874966 hasConceptScore W2979874966C71924100 @default.
• W2979874966 hasConceptScore W2979874966C86803240 @default.
• W2979874966 hasLocation W29798749661 @default.
• W2979874966 hasOpenAccess W2979874966 @default.
• W2979874966 hasPrimaryLocation W29798749661 @default.
• W2979874966 hasRelatedWork W1948059119 @default.
• W2979874966 hasRelatedWork W1998024510 @default.
• W2979874966 hasRelatedWork W2053254222 @default.
• W2979874966 hasRelatedWork W2118341411 @default.
• W2979874966 hasRelatedWork W2547002014 @default.
• W2979874966 hasRelatedWork W2555885038 @default.
• W2979874966 hasRelatedWork W2572225671 @default.
• W2979874966 hasRelatedWork W2583767956 @default.
• W2979874966 hasRelatedWork W2587775779 @default.
• W2979874966 hasRelatedWork W2588153269 @default.
• W2979874966 hasRelatedWork W2590641072 @default.
• W2979874966 hasRelatedWork W2597392223 @default.
• W2979874966 hasRelatedWork W2789178794 @default.
• W2979874966 hasRelatedWork W2978428646 @default.
• W2979874966 hasRelatedWork W2978502618 @default.
• W2979874966 hasRelatedWork W2993240291 @default.
• W2979874966 hasRelatedWork W3029468956 @default.
• W2979874966 hasRelatedWork W3047143384 @default.
• W2979874966 hasRelatedWork W3082392838 @default.
• W2979874966 hasRelatedWork W3157680163 @default.
• W2979874966 isParatext "false" @default.
• W2979874966 isRetracted "false" @default.
• W2979874966 magId "2979874966" @default.
• W2979874966 workType "article" @default.